Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) FCF Margin (2016 - 2025)

Sonoma Pharmaceuticals has reported FCF Margin over the past 16 years, most recently at 18.65% for Q4 2025.

  • For Q4 2025, FCF Margin fell 3444.0% year-over-year to 18.65%; the TTM value through Dec 2025 reached 20.99%, down 2202.0%, while the annual FY2025 figure was 1.18%, 1767.0% up from the prior year.
  • FCF Margin for Q4 2025 was 18.65% at Sonoma Pharmaceuticals, down from 11.51% in the prior quarter.
  • Over five years, FCF Margin peaked at 15.8% in Q4 2024 and troughed at 87.29% in Q1 2023.
  • A 5-year average of 28.97% and a median of 30.78% in 2021 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: surged 9224bps in 2024 and later tumbled -3444bps in 2025.
  • Year by year, FCF Margin stood at 11.27% in 2021, then decreased by -14bps to 12.87% in 2022, then tumbled by -174bps to 35.21% in 2023, then skyrocketed by 145bps to 15.8% in 2024, then tumbled by -218bps to 18.65% in 2025.
  • Business Quant data shows FCF Margin for SNOA at 18.65% in Q4 2025, 11.51% in Q3 2025, and 52.83% in Q2 2025.